U.S. pharma giant copyright scrapped two experimental weight loss capsules final 12 months—a once-each day tablet, lotiglipron, as a consequence of elevated liver enzymes in addition to a 2 times-everyday tablet, danuglipron, because of solid side effects—but CEO Albert Bourla has mentioned the company is determined to “Participate in and win